Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study.

Ana Beatriz Gago-VeigaNoelia Lopez-AlcaideSonia QuintasIris Fernández LázaroJavier Casas-LimónCarlos CalleGermán LatorreNuria González-GarcíaJesús Porta EtessamJaime Rodriguez-VicoAlex JaimesAndrea Gómez GarcíaDavid Garcia Azorin Ángel Luis Guerrero-Peral Álvaro SierraAlberto Lozano RosAntonio Sánchez-SoblecheroJavier Díaz-de-TeranJavier A MembrillaCristina TreviñoAlicia Gonzalez-Martinez

Published in: European journal of neurology (2024)

Anti-CGRP antibodies allow the withdrawal of associated preventive treatment in a significant percentage of patients, which supports its effectiveness in real-life conditions.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
systematic review
prognostic factors
chronic kidney disease
patient reported outcomes
combination therapy
patient reported